Inari Medical, Inc. (NASDAQ:NARI) Given Consensus Rating of “Hold” by Analysts

Shares of Inari Medical, Inc. (NASDAQ:NARI) have received a consensus recommendation of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $58.89.

Several equities analysts recently issued reports on NARI shares. Wells Fargo & Company reduced their price target on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Stifel Nicolaus started coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target on the stock. Robert W. Baird boosted their price target on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft started coverage on shares of Inari Medical in a research report on Friday, August 9th. They set a “buy” rating and a $68.00 price target on the stock. Finally, Canaccord Genuity Group boosted their price target on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday.

Inari Medical Trading Down 4.2 %

NARI stock opened at $47.10 on Thursday. The firm’s 50-day moving average price is $43.51 and its two-hundred day moving average price is $45.96. Inari Medical has a 12-month low of $36.73 and a 12-month high of $67.13. The stock has a market capitalization of $2.74 billion, a price-to-earnings ratio of -37.25 and a beta of 1.00.

Inari Medical (NASDAQ:NARI) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. The firm had revenue of $145.82 million during the quarter, compared to analysts’ expectations of $143.96 million. Equities analysts predict that Inari Medical will post -0.75 EPS for the current year.

Insider Transactions at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the transaction, the director now owns 601,233 shares in the company, valued at approximately $27,067,509.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the transaction, the director now owns 601,233 shares in the company, valued at approximately $27,067,509.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Mitch C. Hill sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now owns 179,600 shares in the company, valued at approximately $8,105,348. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 88,000 shares of company stock worth $4,009,340. Corporate insiders own 10.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NARI. Motley Fool Asset Management LLC lifted its position in Inari Medical by 46.2% during the first quarter. Motley Fool Asset Management LLC now owns 64,677 shares of the company’s stock valued at $3,103,000 after purchasing an additional 20,438 shares during the period. Bamco Inc. NY lifted its position in Inari Medical by 27.4% during the first quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock valued at $37,288,000 after purchasing an additional 167,000 shares during the period. Lighthouse Investment Partners LLC bought a new position in Inari Medical during the second quarter valued at approximately $2,145,000. Integral Health Asset Management LLC lifted its position in Inari Medical by 100.0% during the second quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock valued at $19,260,000 after purchasing an additional 200,000 shares during the period. Finally, Maryland State Retirement & Pension System bought a new position in Inari Medical during the first quarter valued at approximately $886,000. Institutional investors own 90.98% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.